These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
623 related articles for article (PubMed ID: 2512355)
41. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy. Klasa RJ; Silver HK; Kong S Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154 [TBL] [Abstract][Full Text] [Related]
42. Modulation of CD3- large granular lymphocyte functions by agonist and antagonists of protein kinase C: effects on NK and lymphokine-activated killer activity and production of IFN-gamma. Ortaldo JR; Young HA; Varesio L J Immunol; 1989 Jul; 143(1):366-71. PubMed ID: 2543702 [TBL] [Abstract][Full Text] [Related]
43. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285 [TBL] [Abstract][Full Text] [Related]
44. Loxoribine (7-allyl-8-oxoguanosine) activates natural killer cells and primes cytolytic precursor cells for activation by IL-2. Pope BL; Chourmouzis E; Victorino L; MacIntyre JP; Capetola RJ; Lau CY J Immunol; 1993 Sep; 151(6):3007-17. PubMed ID: 8376766 [TBL] [Abstract][Full Text] [Related]
45. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2. Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243 [TBL] [Abstract][Full Text] [Related]
46. Lymphokine-activated effector cells: modulation of activity by cytokines. Mehta S; Flanagan P; Blackinton D; Wanebo H Lymphokine Cytokine Res; 1992 Apr; 11(2):73-7. PubMed ID: 1581419 [TBL] [Abstract][Full Text] [Related]
47. Lymphokine-activated killer (LAK) cells. V. 8-Mercaptoguanosine as an IL-2-sparing agent in LAK generation. Thompson RA; Ballas ZK J Immunol; 1990 Nov; 145(10):3524-31. PubMed ID: 1700014 [TBL] [Abstract][Full Text] [Related]
49. IFN-gamma production and cytotoxicity of IL-2-activated murine NK cells are differentially regulated by MHC class I molecules. Kubota A; Lian RH; Lohwasser S; Salcedo M; Takei F J Immunol; 1999 Dec; 163(12):6488-93. PubMed ID: 10586040 [TBL] [Abstract][Full Text] [Related]
50. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid. Lin TH; Chu TM Cancer Res; 1990 May; 50(10):3013-8. PubMed ID: 1970751 [TBL] [Abstract][Full Text] [Related]
51. Induction of murine lymphokine-activated killer-like cells by Corynebacterium parvum (C. parvum) in vitro: lysis of tumor cells and macrophages by C. parvum-induced killer cells. Chen MF; Suzuki H; Yano S Anticancer Res; 1992; 12(2):451-6. PubMed ID: 1580562 [TBL] [Abstract][Full Text] [Related]
52. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues. Colquhoun SD; Economou JS; Shau H; Golub SH J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167 [TBL] [Abstract][Full Text] [Related]
53. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1. Espevik T; Figari IS; Ranges GE; Palladino MA J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680 [TBL] [Abstract][Full Text] [Related]
54. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation. Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943 [TBL] [Abstract][Full Text] [Related]
55. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity. Ting CC; Hargrove ME; Yun YS J Immunol; 1988 Aug; 141(3):741-8. PubMed ID: 3260909 [TBL] [Abstract][Full Text] [Related]
56. Enhancement of lymphokine-activated killer cell induction using anti-CD25 and anti-CTLA-4 monoclonal antibodies. Okita R; Yamaguchi Y; Emi A; Matsuura K; Toge T Oncol Rep; 2007 Jun; 17(6):1429-35. PubMed ID: 17487401 [TBL] [Abstract][Full Text] [Related]
57. Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy. Favrot M; Capdeville R; Combaret V; Zhou DC; Clapisson G; Banchereau J; Franks CR; Chouaib S; Blay JY; Philip T Eur Cytokine Netw; 1990; 1(3):141-7. PubMed ID: 2129798 [TBL] [Abstract][Full Text] [Related]
58. Release of cytokines during generation of lymphokine-activated killer (LAK) cells by IL-2. Limb GA; Meager A; Woolley J; Wadhwa M; Biggerstaff J; Brown KA; Wolstencroft RA Immunology; 1989 Dec; 68(4):514-9. PubMed ID: 2514140 [TBL] [Abstract][Full Text] [Related]
59. Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production. Handa K; Suzuki R; Matsui H; Shimizu Y; Kumagai K J Immunol; 1983 Feb; 130(2):988-92. PubMed ID: 6294182 [TBL] [Abstract][Full Text] [Related]
60. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells. Gaddy J; Broxmeyer HE Cell Immunol; 1997 Sep; 180(2):132-42. PubMed ID: 9341743 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]